TAPAN KUMAR SINGH NAYAK, MSc, PhD (Continuing) Assistant Professor

Department of Biotechnology, Berhampur University Berhampur, 760007, Odisha Contact No. +91-9542526166/7978705931; Email Id- tapankumarsinghnayak@gmail.com



ACADEMIC DEGREES

- **Ph.D.** [Biotechnology] (Continuing). Dr. Reddy's Institute of Life Sciences, University of Hyderabad
- M.Sc. [Biochemistry] University of Hyderabad

TEACHING & RESEARCH EXPERIENCE

- Assistant Professor, Berhampur University, Berhampur, Odisha since 1st October, 2021 till date
- Assistant Professor, Khallikote University, Berhampur, Odisha since 14th May, 2018 to 31st September 2021

ACADEMIC HONORS & AWARDS

- Qualified CSIR-UGC Junior Research Fellowship (JRF) in Life Sciences in 2010
- Qualified Graduate Aptitude Test for Engineering (GATE) in Life Sciences in 2010

HIGHLIGHTS OF PROFESSIONAL EXPERIENCE

Supervisory Teaching:

• M.Sc. Students-03

RESEARCH INTERESTS

- Broad area of research interest is "Inflammation", and in particular, to understand macrophage inflammatory responses and its various regulations in the area of innate immune response. The current focus of research is on Toll Like Receptor (TLR) signaling and its regulation by ubiquitination and deubiquitination process.
- MicroRNA mediated regulation of macrophage inflammatory responses.

RESEARCH PUBLICATIONS

In peer reviewed reputed journals - 4 (Citation - 18)

- Nayak TK, Alamuru-Yellapragada NP, Parsa KVL. Deubiquitinase USP12 promotes LPS induced macrophage responses through inhibition of IκBα. *Biochem Biophys Res Commun.*_Volume 483, Issue 1, 29 January 2017, pages 69–74 (IF-3.57)
- Talari M, Nayak TK, Kain V, Babu PP, Mishra P, Parsa KVL. MicroRNA-712 restrains Macrophage pro-inflammatory responses by targeting LRRK leading to restoration of insulin stimulated glucose uptake by myoblasts. *Molecular Immunology*. Volume 82, February 2017, Pages 1–9 (IF-4.40)
- Pati A, Padhi S, **Nayak TKS**, Panda AK. Angiotensin-Converting Enzyme 2 Genetic Variants Are Associated with Coronavirus Disease 2019. *J Infect Dis.* 2021 Dec 15;224(12):2181-2183. doi: 10.1093/infdis/jiab531. **(IF-5.02)**
- Panda AK, Padhi S, Pati A, **Nayak TKS**. Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted. *Hum Cell*. 2021 Nov;34(6):1943-1944. doi: 10.1007/s13577-021-00616-x. Epub 2021 Sep 15. **(IF-4.17)**